White-to-brown fat conversion
L-BAIBA dose-dependently induces 'browning' of white adipose tissue (WAT) — converting energy-storing white fat cells into thermogenic brown adipose tissue (BAT) that actively burns calories to generate heat, increasing metabolic rate without stimulants.
Fat oxidation and body composition
Animal models show L-BAIBA increases free fatty acid oxidation and reduces fat mass by approximately 40% vs. control. Human bioavailability data confirms plasma L-BAIBA increases significantly within hours of oral supplementation.
Insulin sensitivity and glycogen storage
A 28-day clinical study showed MitoBurn significantly improved glycogen supercompensation after endurance exercise. L-BAIBA also improves carbohydrate tolerance and insulin sensitivity through AMPK-GLUT4 pathway activation.
Mitochondrial health
L-BAIBA stimulates mitochondrial biogenesis and promotes ketone production, improving cellular energy efficiency. These effects mirror key metabolic adaptations seen with regular endurance exercise.
PGC-1α myokine signaling
During exercise, PGC-1α activation in skeletal muscle triggers L-BAIBA synthesis and release into circulation. L-BAIBA then acts as a hormonal signal to adipose tissue, liver, and other organs — communicating that the body is in an exercise state and should optimize fat metabolism.
UCP1 upregulation in adipose tissue
L-BAIBA activates uncoupling protein 1 (UCP1) expression in white adipocytes, the defining molecular marker of brown/beige fat identity. UCP1 uncouples mitochondrial respiration from ATP synthesis, generating heat and burning calories instead.
AMPK activation and glucose metabolism
L-BAIBA activates AMPK in skeletal muscle and liver, stimulating glucose uptake via GLUT4 translocation, increasing fatty acid oxidation, and promoting glycogen supercompensation post-exercise.
Randomized, double-blind, placebo-controlled crossover study of MitoBurn (250, 500, 1,500 mg) vs. placebo and L-valine in healthy men and women. Published in Journal of Dietary Supplements, 2022.
Healthy men and women. Crossover pharmacokinetic design.
All MitoBurn doses produced significant, dose-dependent increases in plasma L-BAIBA levels above baseline and above the L-valine precursor condition. Established oral bioavailability and safety profile for human use.
28-day study examining MitoBurn supplementation effects on glycogen resynthesis and carbohydrate tolerance after endurance exercise.
Active adults. 28-day supplementation with endurance exercise protocol.
MitoBurn supplementation significantly improved glycogen supercompensation after endurance exercise. Improved carb tolerance and insulin sensitivity observed. Supports use in endurance athletes and metabolic health applications.